Research finds Semaglutide may reduce dementia [Lancet Journal]
- Jul 12, 2024
- 1 min read
Updated: 5 days ago
Hey everyone — this study got my attention, so sharing a quick summary. (Original research at the bottom, as always.)
Researchers set out to check whether semaglutide caused neurological problems. Instead they found the opposite: a 48% lower rate of dementia compared to patients taking sitagliptin (Januvia, a common diabetes drug). The same analysis also found up to 28% lower rates of nicotine misuse and similar drops in cognitive decline versus both sitagliptin and glipizide (Glucotrol).
The study was published in The Lancet's eClinicalMedicine journal and was based on electronic health records rather than a randomized trial — so I'll be straight with you, like always: this is a strong signal, not proof. Professor John Wilding at the University of Liverpool (not involved in the study) cautions we can't assume the same benefit applies to people using semaglutide purely for weight loss, since the doses differ and obesity-only patients weren't included. Novo itself is running a proper Alzheimer's trial to answer that directly.
Why I'm still sharing it: this is the same pattern showing up everywhere in the GLP-1 research — heart, kidneys, liver, inflammation, now possibly brain. These medications keep showing benefits beyond the scale, in study after study, in different organs. At some point the pattern itself becomes the story.
Worth watching. When the Alzheimer's trial reads out, I'll write it up.
-Daryl
Book a FREE consult now <- Click There!
www.pnwmedicalgroup.com
Puyallup: 253-340-2270
Federal Way: 253-363-8877
